◼ Archived
Business
AbbVie Revenue Rises on Strength in Immunology, Neuroscience
AbbVie reports Q3 2026 sales performance aligned with analyst estimates, driven by growth in its immunology and neuroscience portfolios.
1 trends tracked about this subject — the full history, oldest to newest below.
AbbVie reports Q3 2026 sales performance aligned with analyst estimates, driven by growth in its immunology and neuroscience portfolios.